Global Chronic Hepatitis Delta Virus (HDV) Infection Drug Pipeline Insight Report 2022: Comprehensive Insights About 10+ Companies and 10+ Pipeline Drugs – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Chronic Hepatitis Delta Virus (HDV) Infection – Pipeline Insight, 2022” clinical trials has been added to ResearchAndMarkets.com’s offering.
This report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Chronic Hepatitis Delta Virus (HDV) Infection pipeline landscape.
It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
The assessment part of the report embraces, in depth Chronic Hepatitis Delta Virus (HDV) Infection commercial assessment and clinical assessment of the pipeline products under development.
In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Chronic Hepatitis Delta Virus (HDV) Infection collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence Chronic Hepatitis Delta Virus (HDV) Infection R&D. The therapies under development are focused on novel approaches to treat/improve Chronic Hepatitis Delta Virus (HDV) Infection.
Chronic Hepatitis Delta Virus (HDV) Infection Emerging Drugs Chapters
This segment of the Chronic Hepatitis Delta Virus (HDV) Infection report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Chronic Hepatitis Delta Virus (HDV) Infection Emerging Drugs
Lonafarnib: Eiger Biopharmaceuticals
Eiger’s lead drug candidate, Lonafarnib is an orally administered small molecule in development for the treatment of chronic HDV infection. The Phase I and II clinical trials have demonstrated good safety and efficacy. The drug acts by blocking the key enzyme required by HDV virus to replicate which is anticipated to cure the HDV infection.Currently, the drug is in Phase III stage of Clinical trial evaluation for the treatment of Chronic Hepatitis D Virus Infection.
JNJ-73763989: Janssen Pharmaceuticals
Janssen “breakthrough” drug JNJ-73763989 is currently being evaluated for the treatment of chronic hepatitis delta virus infection. The drug is a liver-targeted antiviral class molecule designed to treat HVB and HVD infection via RNA interference mechanism. Currently, the drug is in Phase II stage of Clinical trial evaluation for the treatment of Chronic Hepatitis D Virus Infection.
Chronic Hepatitis Delta Virus (HDV) Infection: Therapeutic Assessment
This segment of the report provides insights about the different Chronic Hepatitis Delta Virus (HDV) Infection drugs segregated based on following parameters that define the scope of the report, such as:
Major Players in Chronic Hepatitis Delta Virus (HDV) Infection
There are approx. 10+ key companies which are developing the therapies for Chronic Hepatitis Delta Virus (HDV) Infection. The companies which have their Chronic Hepatitis Delta Virus (HDV) Infection drug candidates in the mid to advanced stage, i.e. phase III include, Eiger Biopharmaceuticals.
Phases
This report covers around 10+ products under different phases of clinical development like
- Late-stage products (Phase III)
- Mid-stage products (Phase II and Phase I/II)
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
Route of Administration
Chronic Hepatitis Delta Virus (HDV) Infection pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.
Products have been categorized under various ROAs such as
- Subcutaneous
- Intravenous
- Oral
- Intramuscular
- Molecule Type
Products have been categorized under various Molecule types such as
- Small molecules
- Natural metabolites
- Monoclonal antibodies
- Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Chronic Hepatitis Delta Virus (HDV) Infection: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Chronic Hepatitis Delta Virus (HDV) Infection therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Chronic Hepatitis Delta Virus (HDV) Infection drugs.
Chronic Hepatitis Delta Virus (HDV) Infection Report Insights
- Chronic Hepatitis Delta Virus (HDV) Infection Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
Chronic Hepatitis Delta Virus (HDV) Infection Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Key Players
- Janssen Pharmaceuticals
- Eiger Biopharmaceutical
- Pharma Essentia
- Vir Biotechnology, Inc.
- Huahui Health
- Antios Therapeutics
Key Products
- JNJ-73763989
- Lonafarinib
- P1101
- VIR 2218
- VIR 3434
- Nivolumab
- HH 003
- ATI 2173
For more information about this clinical trials report visit https://www.researchandmarkets.com/r/wr0q5q
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
